At DrugVision.ai, we're committed to pushing the boundaries of organoid drug screening by integrating cutting-edge technologies into our high-throughput drug screening pipeline. A key component of this innovation is our newly developed Normalized Organoid Growth Rate (NOGR) metric, specifically tailored for brightfield imaging-based assays. This metric, seamlessly integrated into our workflow via the Orbits Oncology image and data analysis platform, represents a significant leap forward in accurately quantifying cytostatic and cytotoxic drug effects in patient-derived tumor organoid screenings. With the NOGR metric, our in-house pipeline delivers unparalleled precision, empowering clinicians and researchers to make data-driven decisions in personalized cancer treatment strategies and drug development.
Manuscript
Abstract
This study focuses on refining growth-rate-based drug response metrics for patient-derived tumor organoid screening using brightfield live-cell imaging. Traditional metrics like Normalized Growth Rate Inhibition (GR) and Normalized Drug Response (NDR) have been used to assess organoid responses to anticancer treatments but face limitations in accurately quantifying cytostatic and cytotoxic effects across varying growth rates. Here, we introduce the Normalized Organoid Growth Rate (NOGR) metric, specifically developed for brightfield imaging-based assays. A label-free image analysis model was applied to segment organoids precisely, track their growth rates over time, and classify viable and dead organoids. Testing eleven phenotypically distinct pancreatic cancer organoid models with five chemotherapeutics demonstrates that the NOGR metric more effectively captures cytostatic and cytotoxic drug effects compared to existing methods. This approach enhances the biological relevance of drug sensitivity assessments on organoids and offers a valuable tool for advancing personalized cancer treatment strategies.
Comments